Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

300 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
Montgomery SA, Thal LJ, Amrein R. Montgomery SA, et al. Int Clin Psychopharmacol. 2003 Mar;18(2):61-71. doi: 10.1097/00004850-200303000-00001. Int Clin Psychopharmacol. 2003. PMID: 12598816
Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. Thal LJ, et al. Neurology. 2003 Dec 9;61(11):1498-502. doi: 10.1212/01.wnl.0000096376.03678.c1. Neurology. 2003. PMID: 14663031 Clinical Trial.
A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
Thal LJ, Calvani M, Amato A, Carta A. Thal LJ, et al. Neurology. 2000 Sep 26;55(6):805-10. doi: 10.1212/wnl.55.6.805. Neurology. 2000. PMID: 10994000 Clinical Trial.
Trials to slow progression and prevent disease onset.
Thal LJ. Thal LJ. J Neural Transm Suppl. 2000;59:243-9. doi: 10.1007/978-3-7091-6781-6_25. J Neural Transm Suppl. 2000. PMID: 10961435 Review.
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. Thal LJ, et al. Neurology. 1996 Dec;47(6):1389-95. doi: 10.1212/wnl.47.6.1389. Neurology. 1996. PMID: 8960716 Clinical Trial.
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study. Shumaker SA, et al. JAMA. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. JAMA. 2004. PMID: 15213206 Clinical Trial.
Current concepts in mild cognitive impairment.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Petersen RC, et al. Arch Neurol. 2001 Dec;58(12):1985-92. doi: 10.1001/archneur.58.12.1985. Arch Neurol. 2001. PMID: 11735772 Review.
Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials.
Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ; Alzheimer's Disease Cooperative Study Group. Sano M, et al. Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):232-41. doi: 10.1097/01.wad.0000213862.20108.f5. Alzheimer Dis Assoc Disord. 2006. PMID: 17132967 Free PMC article. Clinical Trial.
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Aisen PS, et al. Among authors: thal lj. Curr Alzheimer Res. 2008 Feb;5(1):73-82. doi: 10.2174/156720508783884602. Curr Alzheimer Res. 2008. PMID: 18288935 Clinical Trial.
300 results
Jump to page
Feedback